Rinri Therapeutics, a biotech company born from years of academic research at the University of Sheffield, has been granted approval to begin the world’s first human trial of a cell therapy designed to restore hearing by repairing the auditory nerve itself. Called Rincell-1, the treatment aims to regenerate nerve cells in the inner ear that are essential for transmitting sound signals to the brain—cells that no current treatment can replace.

A New Approach to Hearing Loss

Most people are familiar with hearing loss that comes from damaged hair cells in the inner ear. But in neural hearing loss—seen in conditions like age-related hearing decline (presbycusis) and auditory neuropathy spectrum disorder (ANSD)—the issue lies deeper, in the nerve fibers that connect the ear to the brain. Cochlear implants can help, but only if the auditory nerve is still functional.

Rincell-1 offers something radically new. It uses lab-grown precursor cells—called otic neural progenitor cells—that are designed to mature into working auditory neurons after being delivered directly into the cochlea during cochlear implant surgery. In essence, it’s like rewiring a frayed cable at its core, not just boosting the signal.

“Instead of just amplifying or rerouting sound, we’re aiming to rebuild the broken connection,” said Professor Marcelo Rivolta, the therapy’s lead scientist and co-founder of Rinri Therapeutics.

Trial Details: Who’s In and What’s Next

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a Phase I/IIa trial, which will be conducted at three of the country’s top hearing research centers. The trial will involve 20 adult participants: ten diagnosed with auditory neuropathy spectrum disorder (ANSD) and ten with advanced age-related hearing loss. In each group, half will receive both a cochlear implant and the experimental treatment, Rincell-1, while the rest will be fitted with the implant only.

This isn’t just about seeing whether the treatment works—it’s first about safety. But researchers will also be looking for early signs that the therapy helps regenerate nerve activity. They’ll use real-time data from a monitoring system built into the cochlear implants, as well as speech perception tests and patient feedback.

Within a year of starting, the team expects to gather proof-of-concept data—an early indicator of whether this therapy could become a viable treatment.

Opening a Door Previously Sealed Shut

The auditory nerve endings are buried deep within the skull, protected by bone and difficult to reach. Traditional surgery would require extensive drilling—something too risky and painful for a routine procedure.

Now, thanks to collaborative research across universities in the UK, Canada, and Sweden, a less invasive method has been developed. Described in Nature Scientific Reports, the new approach uses a natural membrane in the inner ear called the round window as a gateway. Through this access point, surgeons can deliver the regenerative cells directly to the site of damage with far less trauma.

“It’s like slipping a message through a mail slot instead of breaking down the front door,” said Professor Doug Hartley, Rinri’s Chief Medical Officer and one of the architects of the new procedure.

Why This Trial Matters

Neural hearing loss impacts more than 100 million people globally, and that number is projected to grow as populations age. Yet treatments have lagged behind, partly because regenerating nerve tissue in the ear was once considered impossible. Rincell-1 is the first attempt to not just manage symptoms but actually change the trajectory of the disease.

The therapy was developed using Rinri’s OSPREY™ platform—a method for producing ready-to-use cell therapies that don’t rely on patient-specific donor cells. That means, if successful, Rincell-1 could one day be available “off-the-shelf,” making it more accessible and affordable than personalized regenerative therapies.

For now, all eyes are on this first trial. It’s the scientific equivalent of planting a seed in long-frozen soil—no guarantees, but a real chance that something once thought lost could grow again.

[Source: 1,2]

The post First Human Trial of Regenerative Cell Therapy Targets Age-Related and Neural Hearing Loss appeared first on Medical Journal Daily.

SPVX02 is formulated using the company’s proprietary StablevaX™ technology, which enables existing vaccines to remain stable at room temperature. In preclinical tests, the vaccine retained its efficacy after undergoing three cycles of temperature fluctuations between -20°C and 40°C. This kind of thermal resilience is rare among biologics and critical to improving vaccine access in low-resource or remote settings.

Tackling Vaccine Waste Through Thermostability

This fridge-free vaccine aims to address a well-documented challenge in global health: vaccine loss due to cold chain failures. According to the World Health Organization, around 50% of vaccines are wasted annually, often because they are compromised during transport or storage. Most conventional vaccines require strict temperature control, typically between 2°C and 8°C. Some even demand sub-zero storage.

SPVX02 has an 18-month shelf life at room temperature, which not only reduces the logistical burden but also minimizes dependence on refrigeration infrastructure. This has significant implications for vaccination campaigns in areas with unreliable electricity or limited refrigeration capacity.

Stablepharma’s innovation could help reduce these inefficiencies, making immunization programs more resilient, particularly during emergencies or in regions with poor access to cold-chain networks.

Government and EU-Backed Research

The current trial is funded through a combination of UK government support and European Union research initiatives. Funding support for the project has come from UK-based innovation bodies, including Innovate UK and NIHR, which back promising health technologies.

In February 2025, the company was awarded €2.5 million from the European Innovation Council Accelerator, following an earlier €50,000 grant from the Horizon Europe program in 2021.

These grants are part of broader efforts to advance vaccine innovation and improve preparedness for future health emergencies.

Professor Saul Faust, Director of the NIHR Southampton Clinical Research Facility, is leading the trial. He emphasized the significance of testing thermostable vaccines in human subjects, noting that it marks a turning point in vaccine delivery research.

Expanding the Platform Beyond SPVX02

Stablepharma views SPVX02 as just the beginning. The company has identified up to 60 existing vaccines that could be reformulated using the StablevaX™ platform. These include vaccines that are currently restricted by cold-chain requirements, such as those for polio, hepatitis, and measles.

Chief Development Officer Dr Karen O’Hanlon stated that SPVX02 demonstrates how thermostable vaccines can be produced at scale under Good Manufacturing Practice (GMP) conditions, paving the way for mass distribution without relying on refrigeration.

Should the trial outcomes remain positive, the company plans to launch SPVX02 commercially by 2027. The company believes that thermostable vaccines could play a key role in improving global vaccine coverage and reducing barriers to access.

Implications for Global Health

Fridge-free vaccines offer a practical solution to a persistent problem in immunization delivery. Their ability to remain effective outside a controlled environment could transform how vaccines are transported, stored, and administered—especially in remote, conflict-affected, or resource-poor regions.

If successful, the SPVX02 trial could validate a scalable model that significantly reduces vaccine spoilage and extends immunization reach.

As the trial progresses, researchers and health policymakers worldwide will be watching closely. The outcome may not only affect future vaccine logistics but also inform the next generation of biologic formulation technologies.

[Source]

The post Stablepharma Tests Fridge-Free Vaccine That Could Help Cut Global Wastage appeared first on Medical Journal Daily.

The Breakthrough

Lp(a) is a type of cholesterol that is inherited and increases the risk of serious heart conditions, such as heart attacks and strokes. Unlike the commonly known “bad” cholesterol (LDL), which can be controlled with diet and medication, there are currently no approved treatments to lower Lp(a).

This new drug could be a game-changer for millions of people worldwide who are at risk due to high Lp(a) levels.

The results of the Phase 2 ALPACA study, presented at the 2025 American College of Cardiology Scientific Sessions and published in the New England Journal of Medicine, showed that lepodisiran provided long-term reductions in Lp(a) levels after just one or two doses.

The drug was tested on 320 adults with elevated Lp(a) levels, who were divided into groups receiving different dosages of the drug. Those who received the highest dose (400 mg) experienced the most dramatic and long-lasting decrease in Lp(a), with levels still 74.2% lower than baseline after 1.5 years.

How Does Lepodisiran Work, and What Does It Mean for Patients?

Lepodisiran is a small interfering RNA (siRNA) therapy. This means it works by targeting the genetic instructions that tell the body to produce Lp(a), reducing its levels in the blood. Unlike daily medications, lepodisiran is administered through an injection, and its effects can last for months.

Here’s a breakdown of the key results from the trial:

Low dose (16 mg): 40.8% reduction in Lp(a)

Medium dose (96 mg): 75.2% reduction in Lp(a)

High dose (400 mg): 93.9% reduction in Lp(a)

For patients, this means that if lepodisiran proves successful in larger trials, they may have access to a treatment that significantly lowers their inherited heart disease risk with as little as one or two injections per year.

This is especially promising for individuals with a strong family history of heart disease, who often struggle to find effective prevention strategies beyond general lifestyle modifications.

Safety and Next Steps

The trial also examined the drug’s safety, and the results were encouraging. No serious side effects related to lepodisiran were reported. Some participants experienced mild reactions at the injection site, particularly at higher doses, but overall, the drug was well tolerated.

In the highest-dose group, only 14% of participants reported mild adverse effects, reinforcing the drug’s potential as a safe treatment option.

Eli Lilly has already started a Phase 3 trial, called ACCLAIM-Lp(a), which will study whether lowering Lp(a) with lepodisiran actually reduces heart attacks and strokes. If successful, this could lead to the first-ever approved treatment for high Lp(a), offering new hope to the estimated 1.4 billion people worldwide affected by this risk factor.

Researchers are optimistic that these findings could pave the way for broader applications of genetic-based therapies in cardiovascular medicine.

While more research is needed, lepodisiran represents a significant advancement in the fight against inherited heart disease. If future trials confirm its benefits, millions of people could soon have access to a long-lasting treatment that helps lower their risk of serious heart conditions.

[Source ]

The post Eli Lilly’s New Drug Shows Promise in Reducing Heart Disease Risk appeared first on Medical Journal Daily.